2025 年 06 月 08 日 北证专精特新（899601）：小而精， 特色更鲜明的优质投资标的 ——北交所发布北证专精特新指数点评 证券分析师 刘靖 A0230512070005 liujing@swsresearch.com 研究支持 吕靖华 A0230124070002 lvjh@swsresearch.com 联系人 吕靖华 (8621)23297818× lvjh@swsresearch.com 策 略 研 究 证 本研究报告仅通过邮件提供给 中庚基金 使用。1 请务必仔细阅读正文之后的各项信息披露与声明 A 股 策 资料来源：Wind，申万宏源研究；截至 2025/6/6 资料来源：Wind，申万宏源研究；截至 2025/6/6 略 券 研 究 报 告 ⚫ 事件：2025 年 6 月 6 日，北交所公告将于 2025 年 6 月 30 日正式发布北证专精特新指 数，经流动性筛选后，北证专精特新指数将从符合条件的北交所专精特新"小巨人"上市 公司中选取市值最大的 50 只作为指数样本，为市场提供多维度投资标的和业绩基准。 ⚫ 北证专精特新聚焦小巨人、特色更鲜明，编制规则采用半年度调仓、调整数量不超 ...

Group 1 - The North Exchange will officially launch the North Specialized and Innovative Index on June 30, 2025, which will provide multi-dimensional investment targets and performance benchmarks [1][9] - The index will consist of the 50 largest "little giant" companies listed on the North Exchange, reflecting the overall performance of specialized and innovative companies [1][9] - As of June 6, 2025, there are 146 national-level specialized and innovative "little giant" companies listed on the North Exchange, accounting for 54.89% of the total [1][14][17] Group 2 - In 2024, the average revenue of national-level specialized and innovative companies on the North Exchange was 613 million yuan, while non-national-level companies had an average revenue of 768 million yuan, with year-on-year changes of -6.88% and +2.40% respectively [1][15] - The average net profit attributable to shareholders for national-level specialized and innovative companies was 47.83 million yuan, compared to 35.16 million yuan for non-national-level companies, with year-on-year changes of -20.72% and -24.34% respectively [1][15] - The gross profit margin for national-level specialized and innovative companies was 25.11%, while for non-national-level companies it was 21.83% [21][24] Group 3 - The North Exchange's A-shares had an average daily trading volume of 24.83 billion yuan, a decrease of 2.38% from the previous week, with a turnover rate of 6.18% [2][30] - The North 50 Index closed at 1427.06 points, with a week-on-week increase of 1.30% and a PE ratio of 74.42X [2][31][35] - The overall PE ratio for North Exchange A-shares increased to 50.21X, with 144 companies having a PE ratio exceeding 45X, accounting for 54.55% [2][33][38] Group 4 - The five major industries on the North Exchange, including high-end equipment, information technology, new chemical materials, consumer services, and biomedicine, have TTM PE ratios of 40.68X, 101.69X, 42.50X, 56.05X, and 51.53X respectively [2][37][39] - The North Exchange focuses on serving innovative small and medium-sized enterprises, particularly in advanced manufacturing and modern service industries, to promote high-quality economic development [1][14]

Group 1: Company Overview and Strategy - The company focuses on real estate development and sales, with a strong presence in the Yangtze River Delta region, adhering to a "long-termism" philosophy and a strategy of "steady operation and progress" [2][3] - The company maintains a "low debt, high return" operational strategy while advancing its dual business model in real estate and medical aesthetics [2][3] Group 2: Real Estate Business Performance - The real estate sector remains under pressure, but market sales data is stabilizing; the company benefits from ample quality land reserves and low land costs, with a total land reserve of over 1.7 million square meters [3] - Key projects like Binjiang Yayuan and Rongjin Ruifu are performing well, with strong sales and high profitability [3][4] Group 3: Future Development Plans in Real Estate - The company plans to continue its high-profit and positive cash flow real estate projects, with new projects set to launch in advantageous areas in the second half of the year [4] - The company will focus on upgrading and launching premium projects while maintaining a stable pricing system [4] Group 4: Medical Aesthetics Business Performance - The company has established six medical aesthetics institutions, creating a distribution pattern across six cities, and is committed to compliance and quality management [5][6] - The revenue and profit from the medical aesthetics sector are gradually increasing, with expectations for significant growth in revenue share by 2026 as new institutions open in the Yangtze River Delta [6] Group 5: Market Conditions and Future Outlook for Medical Aesthetics - The medical aesthetics market is experiencing a slowdown, with increased concentration and the exit of smaller players; however, the company focuses on high-end clientele and maintains a stable pricing strategy [7][8] - The company aims to expand its medical aesthetics business while exploring new industries and opportunities for sustainable growth [8]

Core Viewpoint - The recent announcement by the State Administration for Market Regulation (SAMR) regarding typical cases of illegal advertising highlights the ongoing issues of false advertising and exaggerated claims in the medical and pharmaceutical sectors, necessitating stricter regulatory measures to protect consumer rights and public health [1][3][5]. Regulatory Actions - In April 2023, SAMR issued a notice focusing on five key areas, including medical, pharmaceutical, health food, special medical purpose formula food, and medical device advertising, to enhance market order and consumer protection [1][5]. - The release of the "Medical Advertising Regulatory Work Guidelines" in May 2023 marks a new phase in the regulation of medical advertising, providing clear legal boundaries and institutional support for patient rights and market order [2][6]. Case Examples - Among the ten typical cases of illegal advertising published, six involved the pharmaceutical sector, including a case where a company was fined 194,000 yuan for advertising unapproved medical devices [3][4]. - Other cases included misleading advertisements for medical services and products claiming disease prevention or treatment capabilities, resulting in fines totaling 1.4 million yuan across various cases [3][4]. Enforcement Statistics - As of April 2023, nationwide efforts have led to the investigation of 11,459 illegal advertising cases, with fines totaling approximately 88.31 million yuan [5][6]. - Specific regions, such as Anhui, reported 1,458 leads on illegal medical advertising and 452 cases of violations, demonstrating the effectiveness of local regulatory actions [5]. Future Directions - Experts suggest enhancing the regulatory framework by refining advertising review standards and establishing comprehensive monitoring mechanisms [7]. - The introduction of technology-driven solutions, such as an intelligent monitoring system for medical advertisements, is recommended to improve compliance and enforcement [7].

Core Points - The 2025 Zhejiang-Taiwan Cooperation Week opened in Hangzhou with the theme "Co-cultivating New Quality Productivity, Sharing New Opportunities for Openness" [1] - The event aims to discuss cross-strait economic cooperation and explore long-term development paths, emphasizing high-quality development [1] - Eight key Taiwan-funded projects in industries such as smart manufacturing, medical beauty, and leisure tourism were signed and unveiled during the event [1] Group 1 - The event is part of a comprehensive economic and trade cooperation platform that has been held 11 times since 2013, enhancing cross-strait economic integration and resource sharing [1] - The opening ceremony was attended by representatives from well-known business groups, industry associations, and Taiwanese entrepreneurs, highlighting the importance of collaboration [1] - The establishment of the "Cross-Strait Youth Digital Economy Innovation Base" was announced, indicating a focus on youth engagement in digital economy initiatives [1] Group 2 - The 2025 Zhejiang-Taiwan Cooperation Week continues the "1+X" model, with activities planned in multiple cities including Hangzhou, Ningbo, Wenzhou, Jiaxing, and Shaoxing [2] - The event will feature various thematic economic and trade matching activities, inviting Taiwanese guests to visit cross-strait industrial parks and related cities [2] - The focus areas include digital economy, health, and smart manufacturing, aimed at promoting economic exchanges and innovation development between the two regions [2]

Group 1: Medical Aesthetics Business Development - The company plans to increase investment in the medical aesthetics sector, aiming to enhance the market recognition and reputation of the Suya Medical Aesthetics brand. In 2025, new medical aesthetics institutions are planned to open in Jiangsu and Shanghai [2][3] - In 2024, the medical aesthetics segment achieved revenue of 179 million yuan and is currently profitable. The company will continue to focus on self-built facilities and expand in high-consumption areas like the Yangtze River Delta [5][6] Group 2: Shareholder Engagement and Stock Performance - In 2024, the actual controller and some executives completed a round of share buybacks, demonstrating confidence in the company's long-term investment value [3][4] - The company is committed to a "long-termism" approach, focusing on stable operations and long-term value creation, despite current market pressures affecting stock prices [4][6] Group 3: Strategic Business Direction - The company is dedicated to developing medical aesthetics and biopharmaceuticals, emphasizing a long-term strategy and resource optimization to enhance operational efficiency and profitability [3][5] - Future business expansion will include exploring new industries and opportunities, with a focus on maintaining a balanced approach to growth and avoiding reckless expansion [5][6] Group 4: Market Conditions and Company Response - The company's stock price has been under pressure due to macroeconomic factors, industry developments, and investor expectations. The company aims to improve product quality, brand building, and customer service to enhance overall competitiveness [6][7] - New medical aesthetics facilities are under construction, with plans for trial operations expected around mid-year [6][7]

Core Viewpoint - The article discusses the recent turmoil in the medical aesthetics industry, highlighting the rapid rise and subsequent decline of various medical institutions, particularly in cosmetic surgery and beauty clinics, due to scandals, regulatory changes, and increased competition from public hospitals [4][32]. Group 1: Industry Overview - The Chongqing All-Region Tumor Hospital, which invested 3 billion, has announced a complete halt to operations, reflecting the struggles faced by large medical institutions [4]. - The medical aesthetics sector, once thriving, is now witnessing a wave of closures, with over ten beauty clinics in major cities like Beijing and Shanghai reportedly "running away" within five months [9][11]. - The market for cosmetic procedures has seen significant growth, with the medical aesthetics market size increasing from 796 billion in 2016 to 2,545 billion in 2023, a 3.2 times increase [32]. Group 2: Challenges Faced - The industry is plagued by scandals, including the use of unlicensed practitioners and unsafe products, leading to a loss of consumer trust and a rapid decline in clientele [26][30]. - The number of compliant medical aesthetics institutions has decreased from 13,000 to 9,800 in 2023, with predictions of a further 20% reduction by 2025 [33]. - Public hospitals are entering the medical aesthetics market, offering competitive services that challenge the traditional dominance of private clinics [37]. Group 3: Market Dynamics - The rise of public hospitals offering aesthetic services has shifted consumer preferences, as they provide more transparent and affordable options compared to private clinics [39][43]. - The perception of medical aesthetics has changed, with consumers becoming more discerning and less willing to pay for marketing gimmicks [47]. - Many clinics are resorting to deep discounts and promotions to attract customers, but this approach is not sustainable due to high operational costs [50][51]. Group 4: Future Directions - To survive, medical aesthetics institutions must focus on compliance and enhance service quality, shifting from a one-time transaction model to a more sustainable, ongoing care approach [54][57]. - Companies are encouraged to provide transparent information about procedures and products, fostering trust and meeting genuine consumer needs [58][59]. - The industry must adapt to the changing landscape by offering comprehensive services that prioritize patient care and satisfaction [61].

Group 1 - The overall quality of companies waiting for listing on the Beijing Stock Exchange (BSE) is high, with an average net profit of 89.67 million yuan for 94 companies, significantly higher than the average of 42.11 million yuan for 266 listed companies [3][15][17] - The average subscription rate for companies that raised over 200 million yuan is 0.14%, compared to 0.06% for those that raised less than 200 million yuan, indicating a correlation between fundraising size and subscription success [14][21] - The expected new stock subscription yield for 2025 is estimated to be between 4.8% and 10.80%, based on various assumptions regarding market conditions and investor participation [20][21] Group 2 - The BSE 50 index experienced a decline of 3.68% this week, closing at 1370.04 points, following a previous high of 1500 points, indicating potential volatility in the market [4][25][29] - The overall price-to-earnings (PE) ratio for BSE A-shares has decreased to 48.45X, with 53.79% of companies having a PE ratio exceeding 45X, suggesting a high valuation environment [22][26][27] - The five major industries on the BSE, including high-end equipment and information technology, have varying PE ratios, with information technology at 92.82X, indicating sector-specific valuation disparities [32][34] Group 3 - The average first-day price increase for newly listed companies from January 1, 2024, to May 23, 2025, is 303.91%, with the highest recorded increase being 731.41% for Tongguan Mining [44] - The IPO review process is active, with two companies awaiting approval and two newly accepted for review, reflecting ongoing market activity [5][42] - The report highlights the importance of focusing on companies with stable performance and reasonable valuations, particularly those classified as "little giants" in their respective sectors [39][41]

Investment Rating - The industry investment rating is "Positive" (首次) [2] Core Insights - The report highlights a scientific revolution in the anti-aging field, emphasizing the role of hyaluronic acid (HA) as a key element in extracellular matrix (ECM) aging intervention [5] - Recent studies indicate that high molecular weight HA can extend healthy lifespan in mice, reduce cancer risk, and improve inflammatory responses, suggesting its benefits go beyond traditional moisturizing [5] - The report notes that the repositioning of HA in the scientific community opens new growth opportunities in the anti-aging market [5] Summary by Sections Industry Overview - The report discusses the transition of anti-aging strategies from local interventions to systemic interventions, marking a new era in anti-aging research [5] Company Developments - Huaxi Biotechnology has positioned itself at the forefront of ECM research, with two Class III medical device products recently approved [6] - The first product, "Runbaiyan·Glass," is the first approved water-light product for facial skin quality improvement in China, showing a clinical effectiveness rate of 94% [6] - The second product, "Runzhi·Titu," is the first compliant active ingredient product with a clear indication for facial skin quality improvement [6] Market Positioning - Huaxi Biotechnology leads the HA industry with the largest synthetic biology pilot platform and superior HA raw material preparation capabilities [6] - The company has 11 registered Class III medical devices in aesthetic injections, surpassing competitors like Aimeike and Haohai Biological [6] - The report identifies Huaxi Biotechnology and Aimeike as beneficiaries of the industry's growth [6]

【环球时报驻韩国、新加坡特约记者 黎枳银 辛斌】在美国加征关税压力持续存在的背景下，日本、韩国等亚太多国GDP和贸易出现衰退或下滑趋势。日本 16日宣布其第一季度GDP按年率下降0.7%。韩国权威智库首次预测今年经济增速将降至0.8%，引发"经济衰退"担忧。亚太经合组织（APEC）15日发表报告 警告称，受美国关税政策影响，今年亚太贸易增长可能几乎停滞。不过，与多国对美贸易萎缩相反，这些国家对中国的出口增长明显，中国成为多国经济增 长的重要支撑。与此同时，亚太多国之间，特别是多国与中国正加紧升级自贸协定的谈判，以深化区域经济一体化。16日，APEC贸易部长会议通过联合声 明，与会各方强调加强区域合作，加快自贸协定谈判，以应对当前全球经济环境的不确定性。 正如APEC报告所预测，受美国关税政策影响，亚太多国经济增长面临压力。日本政府16日公布第一季度GDP数据，第一季度GDP环比下降0.2%，按年率下 降0.7%。第一季度出口下降0.6%。《日经亚洲评论》称，这是日本GDP一年来首次出现萎缩。虽然这主要是受通胀高企导致消费乏力影响，但接受日经调 查的众多经济学家担忧，美国关税影响将导致日本GDP全年萎缩0.4至 ...